The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Interleukin 10 (IL-10) upregulates IL-1 receptor antagonist production from lipopolysaccharide-stimulated human polymorphonuclear leukocytes by delaying mRNA degradation.
Open accessAbstract
Polymorphonuclear leukocytes (PMN) have been identified as cells capable of producing a number of pro- and antiinflammatory cytokines in response to specific agonists. Previously, we showed that tumor necrosis factor (TNF), interleukin-1 beta (IL-1 beta), and IL-8, are produced by PMN after stimulation with agonists, such as lipopolysaccharide (LPS). In this study, we demonstrate that LPS is also a potent stimulus for the mRNA expression and release of the IL-1 receptor antagonist (IL-1ra). In addition, we show that the release of IL-1ra from LPS-stimulated PMN is markedly potentiated in the presence of IL-10 (from two to threefold after 18 h of stimulation). Moreover, we observed that this upregulation of IL-1ra production by IL-10 in LPS-stimulated PMN took place through IL-1ra mRNA stabilization. Indeed, the half-life of IL-1ra mRNA was prolonged in PMN stimulated in the presence of IL-10 and LPS, as compared with cells stimulated with LPS alone. That IL-10 selectively upregulates IL-1ra production in LPS-activated PMN, while it inhibits the production of IL-1 beta, TNF, and IL-8 under the same conditions, suggests that IL-10 may be an important physiologic regulator of cytokine production from PMN, and emphasizes the potential role of IL-10 in inflammatory responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interleukin-10-deficient mice develop chronic enterocolitis
Kühn, R., Löhler, J., Rennick, D., Rajewsky, K., & Müller, W. (1993) · Cell · doi:10.1016/0092-8674(93)80068-p · Cited by 4,274
de Waal Malefyt, R., Abrams, J., Bennett, B., Figdor, C. G., & de Vries, J. E. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.5.1209 · Cited by 3,762
IL-10 inhibits cytokine production by activated macrophages
Fiorentino, D. F., Zlotnik, A., Mosmann, T. R., Howard, M., & O’Garra, A. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.11.3815 · Cited by 2,888
Moore, K. (1993) · Annual Review of Immunology · doi:10.1146/annurev.immunol.11.1.165 · Cited by 1,884
Caput, D., Beutler, B., Hartog, K., Thayer, R., Brown-Shimer, S., & Cerami, A. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.6.1670 · Cited by 1,516
Macrophage deactivation by interleukin 10.
Bogdan, C., Vodovotz, Y., & Nathan, C. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.6.1549 · Cited by 1,238
Podolsky, D. K. (1991) · New England Journal of Medicine · doi:10.1056/nejm199109263251306 · Cited by 1,231
Eisenberg, S. P., Evans, R. J., Arend, W. P., Verderber, E., Brewer, M. T., Hannum, C. H., & Thompson, R. C. (1990) · Nature · doi:10.1038/343341a0 · Cited by 1,088
Interleukin-1 Type II Receptor: A Decoy Target for IL-1 That Is Regulated by IL-4
Colotta, F., Re, F., Muzio, M., Bertini, R., Polentarutti, N., Sironi, M., Giri, J. G., Dower, S. K., Sims, J. E., & Mantovani, A. (1993) · Science · doi:10.1126/science.8332913 · Cited by 980
The Role of Interleukin-1 in Disease
Epstein, F. H., Dinarello, C. A., & Wolff, S. M. (1993) · New England Journal of Medicine · doi:10.1056/nejm199301143280207 · Cited by 954
Interleukin-1 receptor antagonist reduces mortality from endotoxin shock
Ohlsson, K., Björk, P., Bergenfeldt, M., Hageman, R., & Thompson, R. C. (1990) · Nature · doi:10.1038/348550a0 · Cited by 853
Gérard, C., Bruyns, C., Marchant, A., Abramowicz, D., Vandenabeele, P., Delvaux, A., Fiers, W., Goldman, M., & Velu, T. (1993) · The Journal of experimental medicine · doi:10.1084/jem.177.2.547 · Cited by 796
Interleukin 10 protects mice from lethal endotoxemia.
Howard, M., Muchamuel, T., Andrade, S., & Menon, S. (1993) · The Journal of experimental medicine · doi:10.1084/jem.177.4.1205 · Cited by 792
Carter, D. B., Deibel, M. R., Dunn, C. J., Tomich, C.-S. C., Laborde, A. L., Slightom, J. L., Berger, A. E., Bienkowski, M. J., Sun, F. F., McEwan, R. N., et al. (1990) · Nature · doi:10.1038/344633a0 · Cited by 601 · cited 1×
“IL-lra is a 23- to 25-kD glycosylated protein, originally purified from supernatants of human monocytes cultured on immune complex-coated surfaces (6), or from the urine of patients with monocytic leukemia (7), which has been recently cloned (8, 9).”
Bogdan, C., Paik, J., Vodovotz, Y., & Nathan, C. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)50091-0 · Cited by 512
Cassatella, M. A., Meda, L., Bonora, S., Ceska, M., & Constantin, G. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.6.2207 · Cited by 507
Self-citationDripps, D. J., Brandhuber, B. J., Thompson, R. C., & Eisenberg, S. P. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)99230-6 · Cited by 452
Lloyd, A. R., & Oppenheim, J. J. (1992) · Immunology Today · doi:10.1016/0167-5699(92)90121-m · Cited by 447
Soluble cytokine receptors are present in normal human urine.
Novick, D., Engelmann, H., Wallach, D., & Rubinstein, M. (1989) · The Journal of experimental medicine · doi:10.1084/jem.170.4.1409 · Cited by 434
A urine inhibitor of interleukin 1 activity that blocks ligand binding.
Seckinger, P., Lowenthal, J. W., Williamson, K., Dayer, J. M., & MacDonald, H. R. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.139.5.1546 · Cited by 345
Cominelli, F., Nast, C. C., Clark, B. D., Schindler, R., Lierena, R., Eysselein, V. E., Thompson, R. C., & Dinarello, C. A. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114799 · Cited by 333
Arend, W. P., Joslin, F. G., & Massoni, R. J. (1985) · The Journal of Immunology · doi:10.4049/jimmunol.134.6.3868 · Cited by 322
Kern, J. A., Lamb, R. J., Reed, J. C., Daniele, R. P., & Nowell, P. C. (1988) · Journal of Clinical Investigation · doi:10.1172/jci113301 · Cited by 316
Cassatella, M. A., Bazzoni, F., Flynn, R. M., Dusi, S., Trinchieri, G., & Rossi, F. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)30495-7 · Cited by 204
Self-citationMcColl, S. R., Paquin, R., Ménard, C., & Beaulieu, A. D. (1992) · The Journal of experimental medicine · doi:10.1084/jem.176.2.593 · Cited by 181
Ulich, T. R., Guo, K., Yin, S., del Castillo, J. M. G., Yi, E. S., Thompson, R. C., & Eisenberg, S. P. (1992) · PubMed Central · Cited by 80
Re, F., Mengozzi, M., Muzio, M., Dinarello, C. A., Mantovani, A., & Colotta, F. (1993) · European Journal of Immunology · doi:10.1002/eji.1830230242 · Cited by 69
Cited by
Interleukin-10 and the Interleukin-10 Receptor
Moore, K. W., de Waal Malefyt, R., Coffman, R. L., & O'Garra, A. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.683 · Cited by 6,737
Mills, E. L., Kelly, B., Logan, A., Costa, A. S. H., Varma, M., Bryant, C. E., Tourlomousis, P., Däbritz, J. H. M., Gottlieb, E., Latorre, I., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.064 · Cited by 2,291
Neutrophils: Molecules, Functions and Pathophysiological Aspects
Witko-Sarsat, V., Rieu, P., Descamps-Latscha, B., Lesavre, P., & Halbwachs-Mecarelli, L. (2000) · Laboratory Investigation · doi:10.1038/labinvest.3780067 · Cited by 1,135
Pro‐ and anti‐inflammatory cytokine balance in strenuous exercise in humans
Ostrowski, K., Rohde, T., Asp, S., Schjerling, P., & Pedersen, B. K. (1999) · The Journal of Physiology · doi:10.1111/j.1469-7793.1999.287ad.x · Cited by 1,014
“Furthermore the antiinflammatory cytokine IL-10 inhibits the release of TNFá and IL-1â (Chernoff et al. 1995), and induces the production of IL-1ra (Jenkins et al. 1994; Cassatella et al. 1994).”
BackgroundInterleukin-10 Therapy—Review of a New Approach
Asadullah, K., Sterry, W., & Volk, H. D. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.2.4 · Cited by 946
Metadata
- Authors
- Cassatella, M. A., Meda, L., Gasperini, S., Calzetti, F., & Bonora, S.
- Venue
- The Journal of experimental medicine
- Publisher
- Rockefeller University Press
- Published
- 1994-05-01
- Volume
- 179
- Issue
- 5
- Pages
- 1695-1699
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2133584066
- Cited by
- 284
- References
- 27
- FWCI
- 8.44
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.